| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA792: Filgotinib for treating moderately to severely active ulcerative colitis |
|
Medicine details |
|
| Medicine name | filgotinib (Jyseleca®) |
| Formulation | 100 mg, 200 mg film coated tablets |
| Reference number | 3402 |
| Indication | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent |
| Company | Gilead Sciences Ltd |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/10/2021 |
| NICE guidance | TA792: Filgotinib for treating moderately to severely active ulcerative colitis |
| Commercial arrangement | PAS |